Judy C Boughey1, Tanya L Hoskin2, Matthew P Goetz3. 1. Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Boughey.judy@mayo.edu. 2. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. 3. Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Neoadjuvant chemotherapy (NAC) is standard for most triple-negative and human epidermal growth factor receptor 2 (HER2)+ breast cancers, and frequently downstages node-positive (cN+) disease, permitting omission of axillary dissection. In estrogen receptor (ER)+/HER2- disease, response rates are lower. Whether Ki67 is associated with axillary downstaging in ER+/HER2- disease is unknown. METHODS: With institutional review board approval, we queried our institutional database to identify all patients with primary ER+/HER2- biopsy-proven cN+ breast cancer treated with NAC followed by surgery from January 2012 to December 2021. Nodal pathologic complete response (pCR) rates were evaluated by pretreatment Ki67 and patient age. RESULTS: 315 patients (median age 50 years) were included. Nodal pCR rate was 24.8% (78/315) and was higher in patients aged < 50 years than ≥ 50 years (31.8% versus 17.7%, p = 0.004). Ki67 was available on 236 patients (74.9%). Median Ki67 was 29.0% (range 1-98%) and did not differ by age category (p = 0.23). Patients with nodal pCR had higher Ki67 (median 40.3% versus 25.0%, p < 0.001). Nodal pCR rates were 28.4% (Ki67 ≥ 20%) versus 8.1% (Ki67 < 20%) (p < 0.001). On multivariable analysis, Ki67 and age category were predictive of nodal pCR. Combining these two parameters together, nodal pCR rates in age < 50 years were 35.8% when Ki67 ≥ 20% versus 14.3% with Ki67 < 20% (p = 0.02). In contrast, for age ≥ 50 years, nodal pCR was 21.0% for Ki67 ≥ 20% versus 2.6% with Ki67 < 20% (p = 0.008). CONCLUSIONS: In ER+/HER2- breast cancer, nodal downstaging with NAC is associated with age (< 50 years) and Ki67 (≥ 20%). Age and Ki67 should be considered for NAC decision-making and can identify patients with high rates of nodal downstaging (36%) who would benefit from NAC to enable axillary preservation.
BACKGROUND: Neoadjuvant chemotherapy (NAC) is standard for most triple-negative and human epidermal growth factor receptor 2 (HER2)+ breast cancers, and frequently downstages node-positive (cN+) disease, permitting omission of axillary dissection. In estrogen receptor (ER)+/HER2- disease, response rates are lower. Whether Ki67 is associated with axillary downstaging in ER+/HER2- disease is unknown. METHODS: With institutional review board approval, we queried our institutional database to identify all patients with primary ER+/HER2- biopsy-proven cN+ breast cancer treated with NAC followed by surgery from January 2012 to December 2021. Nodal pathologic complete response (pCR) rates were evaluated by pretreatment Ki67 and patient age. RESULTS: 315 patients (median age 50 years) were included. Nodal pCR rate was 24.8% (78/315) and was higher in patients aged < 50 years than ≥ 50 years (31.8% versus 17.7%, p = 0.004). Ki67 was available on 236 patients (74.9%). Median Ki67 was 29.0% (range 1-98%) and did not differ by age category (p = 0.23). Patients with nodal pCR had higher Ki67 (median 40.3% versus 25.0%, p < 0.001). Nodal pCR rates were 28.4% (Ki67 ≥ 20%) versus 8.1% (Ki67 < 20%) (p < 0.001). On multivariable analysis, Ki67 and age category were predictive of nodal pCR. Combining these two parameters together, nodal pCR rates in age < 50 years were 35.8% when Ki67 ≥ 20% versus 14.3% with Ki67 < 20% (p = 0.02). In contrast, for age ≥ 50 years, nodal pCR was 21.0% for Ki67 ≥ 20% versus 2.6% with Ki67 < 20% (p = 0.008). CONCLUSIONS: In ER+/HER2- breast cancer, nodal downstaging with NAC is associated with age (< 50 years) and Ki67 (≥ 20%). Age and Ki67 should be considered for NAC decision-making and can identify patients with high rates of nodal downstaging (36%) who would benefit from NAC to enable axillary preservation.
Authors: Brittany L Murphy; Courtney N Day; Tanya L Hoskin; Elizabeth B Habermann; Judy C Boughey Journal: Ann Surg Oncol Date: 2018-05-21 Impact factor: 5.344
Authors: Kevin Kalinsky; William E Barlow; Julie R Gralow; Funda Meric-Bernstam; Kathy S Albain; Daniel F Hayes; Nancy U Lin; Edith A Perez; Lori J Goldstein; Stephen K L Chia; Sukhbinder Dhesy-Thind; Priya Rastogi; Emilio Alba; Suzette Delaloge; Miguel Martin; Catherine M Kelly; Manuel Ruiz-Borrego; Miguel Gil-Gil; Claudia H Arce-Salinas; Etienne G C Brain; Eun-Sook Lee; Jean-Yves Pierga; Begoña Bermejo; Manuel Ramos-Vazquez; Kyung-Hae Jung; Jean-Marc Ferrero; Anne F Schott; Steven Shak; Priyanka Sharma; Danika L Lew; Jieling Miao; Debasish Tripathy; Lajos Pusztai; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2021-12-01 Impact factor: 91.245
Authors: Judy C Boughey; Linda M McCall; Karla V Ballman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa Flippo-Morton; Kelly K Hunt Journal: Ann Surg Date: 2014-10 Impact factor: 12.969
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge Journal: N Engl J Med Date: 2018-06-03 Impact factor: 91.245
Authors: Larissa A Korde; Mark R Somerfield; Lisa A Carey; Jennie R Crews; Neelima Denduluri; E Shelley Hwang; Seema A Khan; Sibylle Loibl; Elizabeth A Morris; Alejandra Perez; Meredith M Regan; Patricia A Spears; Preeti K Sudheendra; W Fraser Symmans; Rachel L Yung; Brittany E Harvey; Dawn L Hershman Journal: J Clin Oncol Date: 2021-01-28 Impact factor: 44.544
Authors: Christina Yau; Marie Osdoit; Marieke van der Noordaa; Sonal Shad; Jane Wei; Diane de Croze; Anne-Sophie Hamy; Marick Laé; Fabien Reyal; Gabe S Sonke; Tessa G Steenbruggen; Maartje van Seijen; Jelle Wesseling; Miguel Martín; Maria Del Monte-Millán; Sara López-Tarruella; Judy C Boughey; Matthew P Goetz; Tanya Hoskin; Rebekah Gould; Vicente Valero; Stephen B Edge; Jean E Abraham; John M S Bartlett; Carlos Caldas; Janet Dunn; Helena Earl; Larry Hayward; Louise Hiller; Elena Provenzano; Stephen-John Sammut; Jeremy S Thomas; David Cameron; Ashley Graham; Peter Hall; Lorna Mackintosh; Fang Fan; Andrew K Godwin; Kelsey Schwensen; Priyanka Sharma; Angela M DeMichele; Kimberly Cole; Lajos Pusztai; Mi-Ok Kim; Laura J van 't Veer; Laura J Esserman; W Fraser Symmans Journal: Lancet Oncol Date: 2021-12-11 Impact factor: 54.433